Vertex Pharmaceuticals (VRTX)
366.54
-9.09 (-2.42%)
NASDAQ · Last Trade: Aug 11th, 12:08 AM EDT
Detailed Quote
Previous Close | 375.63 |
---|---|
Open | 377.03 |
Bid | 367.00 |
Ask | 367.50 |
Day's Range | 364.66 - 381.00 |
52 Week Range | 364.66 - 519.88 |
Volume | 3,680,289 |
Market Cap | 95.09B |
PE Ratio (TTM) | 26.14 |
EPS (TTM) | 14.0 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 2,069,603 |
Chart
About Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals is a biotechnology company that focuses on discovering, developing, and commercializing innovative therapies to treat serious diseases. With an emphasis on cystic fibrosis, Vertex has pioneered groundbreaking treatments that significantly improve the lives of patients with this genetic disorder. In addition to its work in cystic fibrosis, the company is exploring potential therapies for other rare diseases, including pain management and beta-thalassemia. Vertex is dedicated to advancing scientific research and collaborating with the global medical community to bring new solutions to unmet medical needs. Read More
News & Press Releases
Large-cap laggards slid on weak results/guidance, cuts and capital moves—led by The Trade Desk, Fortinet, Super Micro, Gartner and Eli Lilly.
Via Benzinga · August 10, 2025
There's no guarantee that any stock will beat the market, but the chances look good for these three.
Via The Motley Fool · August 9, 2025
Even with the S&P 500 near an all-time high, there are plenty of compelling growth, dividend, and value stocks to buy now.
Via The Motley Fool · August 8, 2025
Curious about which S&P500 stocks are generating unusual volume on Thursday? Find out below.
Via Chartmill · August 7, 2025
Vertex Stock Sinks 12% As Pipeline Setbacks Trigger Wall Street Skepticism: But Retail Sees Opportunitystocktwits.com
Via Stocktwits · August 5, 2025
Market volatility could increase in the months ahead, but these stocks should hold up well.
Via The Motley Fool · August 7, 2025
Let's take a closer look at the S&P500 stocks with an unusual volume in today's session on Wednesday. Stay informed about the market activity below.
Via Chartmill · August 6, 2025
Let's have a look at what is happening on the US markets in the middle of the day on Wednesday. Below you can find the top S&P500 gainers and losers in today's session.
Via Chartmill · August 6, 2025
There's more good news than bad news for this big biotech stock.
Via The Motley Fool · August 6, 2025
Vertex Pharmaceuticals (VRTX) offers strong growth, solid profitability, and reasonable valuations, making it a top pick for affordable growth investors.
Via Chartmill · August 6, 2025
A weaker-than-expected ISM services report reignited fears of a slowing U.S. economy, dragging major indices into the red.
Via Chartmill · August 6, 2025
Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX)
fell 17.4% in the afternoon session after the company announced its experimental pain drug, VX-993, failed a key mid-stage clinical trial. The company’s experimental non-opioid painkiller, VX-993, failed to achieve a statistically significant pain reduction compared to a placebo in a mid-stage study. The trial involved patients who had undergone bunionectomy surgery. Following the failure, Vertex Pharmaceuticals stated it would stop the development of VX-993 as a standalone treatment for acute pain. This setback in the company's drug pipeline overshadowed its recently reported strong second-quarter financial results. The news also compounded concerns after the company revealed that expanding the approval for another pain medicine, Journavx, also faced regulatory hurdles.
Via StockStory · August 5, 2025
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Tuesday.
Via Chartmill · August 5, 2025
The financial markets have been on a tumultuous ride in early August 2025, experiencing a dramatic "see-saw" pattern that has left investors both wary and hopeful. Following a sharp decline at the close of July, Wall Street staged a significant rebound on August 4th, largely propelled by robust gains in
Via MarketMinute · August 5, 2025
Vertex stock falls after pain drug VX-993 fails Phase 2 trial, despite better-than-expected Q2 earnings and strong cystic fibrosis drug sales.
Via Benzinga · August 5, 2025
Via Benzinga · August 5, 2025
Via Benzinga · August 5, 2025
Let's have a look at the S&P500 stocks with an unusual volume in today's session.
Via Chartmill · August 5, 2025
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session.
Via Chartmill · August 5, 2025
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Tuesday to uncover the stocks that are gapping in the S&P500 index.
Via Chartmill · August 5, 2025
Via Benzinga · August 5, 2025
Stay updated with the S&P500 stocks that are on the move in today's pre-market session.
Via Chartmill · August 5, 2025
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via Chartmill · August 5, 2025